protein

Recombinant Human Protein Kinase A regulatory subunit-1 alpha

MBS142748

0.005 mg

375 USD

Recombinant Protein

Recombinant Human Protein Kinase A regulatory subunit-1 alpha

Kinase A regulatory subunit-1 alpha

PKAR-I alpha Human; Protein Kinase A regulatory subunit-1 alpha Human Recombinant; cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1; PRKAR1A PKR1; PRKAR1; CAR; CNC; CNC1; PKR1; ADOHR; PPNAD1; ACRDYS1

cAMP-dependent protein kinase type I-alpha regulatory subunit isoform a; cAMP-dependent protein kinase type I-alpha regulatory subunit; cAMP-dependent protein kinase type I-alpha regulatory subunit; Carney complex type 1; cAMP-dependent protein kinase regulatory subunit RIalpha; cAMP-dependent protein kinase type I-alpha regulatory chain; protein kinase A type 1a regulatory subunit; tissue-specific extinguisher 1; protein kinase, cAMP-dependent, regulatory, type I, alpha; Tissue-specific extinguisher 1; TSE1

PKAR-1a

PRKAR1A; PRKAR1A; CAR; CNC; CNC1; PKR1; TSE1; ADOHR; PPNAD1; PRKAR1; ACRDYS1; PKR1; PRKAR1; TSE1; TSE1

KAP0_HUMAN

E Coli

381

Greater than 95% as determined by SDS-PAGE.

PKA regulatory subunit-I alpha is supplied at a concentration of 1.3 mg/ml in 20mM MOPS (pH 7.0), 150mM NaCl, 1mM 2-mercaptoethanol and 50% glycerol. Sterile Filtered clear solution.

PKAR-Ia should be stored at 4 degree C if entire vial will be used within 2-4 weeks. For long term storage it is recommended to store at -20 degree C. Avoid multiple freeze-thaw cycles.

Inhibitory Activity: The cAMP-dependent protein kinase, regulatory subunit RIa reversibly inhibits the catalytic subunit Ca of the cAMP-dependent protein kinase PKA. The inhibition of the catalytic subunit can be reversed by the addition of the second messenger cAMP.

PROTEIN KINASES; Enzymes; Protein Kinase-A

Description: PKA regulatory subunit I a Human Recombinant is a dimeric 86kDa protein (the monomer is 381 aa 43kDa). PKAR-I alpha is purified by proprietary chromatographic techniques. Introduction: The Regulatory (R) subunit of Protein Kinase A (PKA) inhibits its kinase activity by shielding the Catalytic (C) subunit from physiological substrates. This inhibition is reversed in response to extra-cellular signals that increase cAMP levels in the cytoplasm. Upon cAMP binding to R, C is allosterically released from R, activating a spectrum of downstream signaling cascades. Crystallographic data indicated that a series of distinct conformational changes within CBD-A must occur to relay the cAMP signal from the cAMP binding site to the R:C interaction interface. One critical cAMP relay site within the CBD-A of R has been identified as Asp170 because the D170A mutation selectively reduces the negative cooperativity between the cAMP- and C-recognition sites (i.e. the KD for the R:C complex in the presence of cAMP is reduced by more than 12-fold), without significantly compromising the high affinity of R for both binding partners.

443497964

NP_001263218.1

NM_001276289.1

P10644

38,003 Da

Apoptosis Pathway (83060); Apoptosis Pathway (470); Aquaporin-mediated Transport Pathway (187187); Ca-dependent Events Pathway (106497); CaM Pathway (106468); Calcium Regulation In The Cardiac Cell Pathway (198906); Calmodulin Induced Events Pathway (106469); DAG And IP3 Signaling Pathway (477115); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550)

cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. This gene encodes one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Mutations in this gene cause Carney complex (CNC). This gene can fuse to the RET protooncogene by gene rearrangement and form the thyroid tumor-specific chimeric oncogene known as PTC2. A nonconventional nuclear localization sequence (NLS) has been found for this protein which suggests a role in DNA replication via the protein serving as a nuclear transport protein for the second subunit of the Replication Factor C (RFC40). Several alternatively spliced transcript variants encoding two different isoforms have been observed. [provided by RefSeq, Jan 2013]

PKAR1A: a regulatory subunit of cAMP-regulated protein kinase. The inactive form of the enzyme is composed of two regulatory chains and two catalytic chains. Activation by cAMP produces two active catalytic monomers and a regulatory dimer that binds four cAMP molecules. Four types of regulatory chains are found: I-alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible. Interacts with RFC2: the complex may be involved in cell survival. Defects in PRKAR1A are the cause of Carney complex type 1 (CNC1). CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas. Protein type: Protein kinase, regulatory subunit. Chromosomal Location of Human Ortholog: 17q24.2. Cellular Component: protein complex; membrane; plasma membrane; cytosol; neuromuscular junction; AMP-activated protein kinase complex; cAMP-dependent protein kinase complex. Molecular Function: protein binding; ubiquitin protein ligase binding; cAMP-dependent protein kinase inhibitor activity; cAMP-dependent protein kinase regulator activity; cAMP binding. Biological Process: epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; nerve growth factor receptor signaling pathway; water transport; activation of protein kinase A; female meiosis; cardiac muscle cell proliferation; sarcomere organization; signal transduction; regulation of transcription from RNA polymerase II promoter; mesoderm formation; phospholipase C activation; negative regulation of meiosis; energy reserve metabolic process; innate immune response; renal water homeostasis; blood coagulation; regulation of insulin secretion; transmembrane transport. Disease: Myxoma, Intracardiac; Carney Complex, Type 1; Thyroid Carcinoma, Papillary; Acrodysostosis 1 With Or Without Hormone Resistance; Pigmented Nodular Adrenocortical Disease, Primary, 1

0.005 mg

375 USD

0.025 mg

930

0.05 mg

1530